Pulse nav.journalClub Debates ativos Tendências Explorar Pesquisadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidade

Início Explorar nav.journalClub Tendências

⌘+K

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression | Synapse

June 29, 2017Open Access

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression

Key Points

Key points are not available for this paper at this time.

Abstract

clinicaltrials.gov Identifiers: NCT01721772 (CheckMate 066) and NCT01844505 (CheckMate 067).

Perguntar à IA

Like

Bookmark

Share

View Full Paper

Cite This Study

Long et al. (Thu,) studied this question.

synapsesocial.com/papers/69d92573e0d31bb747835ee3 https://doi.org/https://doi.org/10.1001/jamaoncol.2017.1588

Perguntar à IA

Like

Bookmark

Share

View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression2016 · 178 citations
2The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.2008 · 166 citations
3Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.2015 · 100 citations
4Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.2015 · 20 citations
5Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.2016 · 16 citations